Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
Mural Oncology Announces Sanction of the Scheme by the High Court
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, ARIS, MURA on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Reminds Shareholders of Upcoming Merger Deadlines - AMWD, PHLT, ARIS, and MURA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, ARIS, MURA on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - AMWD, PHLT, ARIS, and MURA
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.